PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29456350-15	2018	Furthermore, a decreased expression of TOP2A observed in the recurrent tumors could probably be due to reduction in chemosensitivity to temozolomide, which has been shown in earlier studies.	Temozolomide	136-148	DNA topoisomerase II alpha	Homo sapiens	39-44	
30038716-9	2018	Temozolomide inhibits transcription of TOP2A, AURKB, KIF20A and does not have any effect on CDC2 and CDC20 and induces p21.	Temozolomide	0-12	DNA topoisomerase II alpha	Homo sapiens	39-44	
22102081-0	2012	Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.	Temozolomide	148-160	DNA topoisomerase II alpha	Homo sapiens	166-171	
22102081-6	2012	The ability of TOP2A enzyme to relax the super coiled plasmid DNA in the presence of temozolomide was evaluated to assess its effect on TOP2A.	Temozolomide	85-97	DNA topoisomerase II alpha	Homo sapiens	15-20	
22102081-7	2012	The temozolomide cyctotoxicity of TOP2A-silenced U251 cells was assessed.	Temozolomide	4-16	DNA topoisomerase II alpha	Homo sapiens	34-39	
22102081-11	2012	Interestingly, we noted that temozolomide inhibited TOP2A activity in in-vitro enzyme assays.	Temozolomide	29-41	DNA topoisomerase II alpha	Homo sapiens	52-57	
22102081-12	2012	We also noted that siRNA knock down of TOP2A rendered a glioma cell line resistant to temozolomide chemotherapy.	Temozolomide	86-98	DNA topoisomerase II alpha	Homo sapiens	39-44	
22102081-13	2012	We demonstrated for the first time that temozolomide is also a TOP2A inhibitor and established that TOP2A transcript levels determine the chemosensitivity of glioblastoma to temozolomide therapy.	Temozolomide	40-52	DNA topoisomerase II alpha	Homo sapiens	63-68	
22102081-13	2012	We demonstrated for the first time that temozolomide is also a TOP2A inhibitor and established that TOP2A transcript levels determine the chemosensitivity of glioblastoma to temozolomide therapy.	Temozolomide	40-52	DNA topoisomerase II alpha	Homo sapiens	100-105	
22102081-13	2012	We demonstrated for the first time that temozolomide is also a TOP2A inhibitor and established that TOP2A transcript levels determine the chemosensitivity of glioblastoma to temozolomide therapy.	Temozolomide	174-186	DNA topoisomerase II alpha	Homo sapiens	100-105	
22102081-14	2012	Very high levels of TOP2A are a good prognostic indicator in GBM patients receiving temozolomide chemotherapy.	Temozolomide	84-96	DNA topoisomerase II alpha	Homo sapiens	20-25